Bakersfield Dermatology and Skin Cancer Medical Group Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2017
NCT03217734
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Bakersfield Dermatology and Skin Cancer Medical Group | Bakersfield Dermatology & Skin Cancer Medical Group | Jeffrey J Crowley MD

Active Ingredients

Drugs in Phase 3 Trials (2)

adalimumab (humira) (1 trial)

methotrexate (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Psoriasis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 2